Zhejiang Shengda Bio-Pharm (603079) Stock Overview
Develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
603079 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Zhejiang Shengda Bio-Pharm Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.89 |
| 52 Week High | CN¥21.21 |
| 52 Week Low | CN¥11.46 |
| Beta | 0.22 |
| 1 Month Change | -2.09% |
| 3 Month Change | -3.32% |
| 1 Year Change | 35.99% |
| 3 Year Change | 34.15% |
| 5 Year Change | -37.97% |
| Change since IPO | 52.34% |
Recent News & Updates
Recent updates
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Plunge Could Signal Some Risk
Jan 12
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%
Oct 28What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You
Aug 08Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive
Jun 12Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues
Apr 25Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Mar 08Shareholder Returns
| 603079 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.0% | 0.7% | 1.8% |
| 1Y | 36.0% | 17.6% | 24.1% |
Return vs Industry: 603079 exceeded the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 603079 exceeded the CN Market which returned 24.1% over the past year.
Price Volatility
| 603079 volatility | |
|---|---|
| 603079 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 603079 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603079's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,035 | Bin Zhou | www.sd-pharm.com |
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin and natamycin; and intermediate APIs. The company is based in Tiantai, China.
Zhejiang Shengda Bio-Pharm Co., Ltd. Fundamentals Summary
| 603079 fundamental statistics | |
|---|---|
| Market cap | CN¥3.16b |
| Earnings (TTM) | CN¥50.74m |
| Revenue (TTM) | CN¥843.66m |
Is 603079 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603079 income statement (TTM) | |
|---|---|
| Revenue | CN¥843.66m |
| Cost of Revenue | CN¥645.46m |
| Gross Profit | CN¥198.20m |
| Other Expenses | CN¥147.46m |
| Earnings | CN¥50.74m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 23.49% |
| Net Profit Margin | 6.01% |
| Debt/Equity Ratio | 17.9% |
How did 603079 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 20:28 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Shengda Bio-Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.